Table 2 Costs and utilities used in the reference case and sensitivity analyses.

	Point estimate and 95% CI
Total costs (FC) of AS if BASDAI ⩾4*	4996 (3830 to 6737)
Total costs (FC) of AS if BASDAI <4*	2456 (1825 to 3275)
Direct costs of AS if BASDAI ⩾4	4686
Direct costs of AS if BASDAI <4	1671
Total costs (HC) of AS if BASDAI ⩾4	15 950
Total costs (HC) of AS if BASDAI <4	10 453
Treatment costs for etanercept	13 759
Treatment costs for infliximab first cycle (€/patient)	7385
Treatment costs for infliximab	21 335
Treatment costs for low dose infliximab first cycle (€/patient)	3974
Treatment costs for low dose infliximab	8612
Screening and prophylaxis TB (€)	82
Treatment toxicity (€)	2007
EQ‐5Dtime averaged if BASDAI ⩾4	0.59 (0.55 to 0.63)
EQ‐5Dtime averaged if BASDAI <4	0.76 (0.74 to 0.79)
EQ‐5D if BASDAI <4 and toxicity present	0.5 (0 to 1.0)* utility BASDAI <4

Values are €/patient/year unless stated otherwise.

*CI based on the 95th centile method of bootstrapped costs.

AS, ankylosing spondylitis; BASDAI, Bath ankylosing spondylitis disease activity index; BASFI, Bath ankylosing spondylitis functional index; CI, confidence interval; EQ‐5D, EuroQol 5 dimensions; FC, friction costs method; HC, human capital approach; TB, tuberculosis.